Related News
New drugs needed to tackle superbugs
Source: Agencies |
September 17, 2009, Thursday
|
Online Edition
Online Edition
EUROPEAN health agencies warn there are not enough new drugs under development to tackle the growing problem of superbugs in Europe.
In a joint report, the European Centre for Disease Control and the European Medicines Agency urge policy-makers to set up global and European strategies to address the problem of multidrug-resistant bacteria.
They say around 25,000 patients die in the European Union each year from antibiotic-resistant bacteria, which costs society 1.5 billion euro (US$2.2 billion) a year.
Today's report said only 15 new anti-bacterial drugs are under development, most of which are in very early stages.
MRSA, or methicillin-resistant Staphylococcus aureus, is the most common superbug, but others are increasing steadily.
In a joint report, the European Centre for Disease Control and the European Medicines Agency urge policy-makers to set up global and European strategies to address the problem of multidrug-resistant bacteria.
They say around 25,000 patients die in the European Union each year from antibiotic-resistant bacteria, which costs society 1.5 billion euro (US$2.2 billion) a year.
Today's report said only 15 new anti-bacterial drugs are under development, most of which are in very early stages.
MRSA, or methicillin-resistant Staphylococcus aureus, is the most common superbug, but others are increasing steadily.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
